| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., November 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the thir... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., August 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second... |
| 01 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company. In connection with her appointment, Dr. Hannah resigned f... |
| 17 Jun 2026 |
8-K: Completion of Acquisition or Disposition of Assets
As previously disclosed in the Current Report on Form 8-K filed by Rigel Pharmaceuticals, Inc. (the “Company”) on May 12, 2026, the Company entered into a License Agreement (the “License Agreement”) with Arvinas, Inc., Arvinas Operations... |
| 20 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On May 14, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Rigel Pharmaceuticals, Inc. (the “Company”), the Company’s stockholders approved an amendment to the Company’s 2018 Equity Incentive Plan, as amended (... |
| 12 May 2026 |
8-K: Entry into a Material Definitive Agreement
On May 11, 2026, Rigel Pharmaceuticals, Inc. (“Rigel” or the “Company”) entered into a License Agreement (the “Agreement”) with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the “... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., May 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the first qua... |
| 21 Apr 2026 |
8-K: Termination of a Material Definitive Agreement
On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreem... |
| 03 Mar 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., March 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth ... |
| 03 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 1, 2026 (the “Effective Date”), Michael P. Miller was appointed to serve on the board of directors (the “Board”) of Rigel Pharmaceuticals, Inc. (“Rigel” or the “Company”), upon the recommendation of the Board’s Corporate Gove... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Other Events
SOUTH SAN FRANCISCO, Calif., January 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including pr... |
| 10 Dec 2025 |
8-K: Other Events
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million |
| 23 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On May 22, 2025, at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Rigel Pharmaceuticals, Inc. (the “Company”), the Company’s stockholders approved the amendment to the Company’s 2018 Equity Incentive Plan, as amended ... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million |
| 27 Mar 2025 |
8-K: Other Events
SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc... |
| 10 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 04 Mar 2025 |
8-K: Results of Operations and Financial Condition
Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million |
Loading...